Search results for: France
Filter search results
Important Variations in Access to Orphan Drugs in France, Italy, Germany, Spain and the UK
14 March 2017
A new OHE report compares the availability and access of orphan medicinal products (OMPs) in the UK, France, Germany, Italy and Spain. A new OHE Consulting Report has been published…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
…new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz summarised changes implemented or being discussed in pricing and reimbursement/HTA systems in France, Germany and the UK. In Germany and France,…
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
Most countries regulate manufacturer prices for pharmaceuticals, either directly (France, Italy) or indirectly through controls on reimbursement (Germany, Japan) or profits (the UK). It is widely believed that drug prices…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
…volume and sales were lower in the UK than in France and the US. Not surprisingly, additional licensed indications produced higher sales. However, for France and the UK, special access…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…beyond 30 years at a lower rate26, as does France5. In France, HAS recommends a discount rate of 2.5% for costs and effects occurring in the first 30 years after…
Data Governance Arrangements for Real-World Evidence in Japan
1 September 2019
In 2015, OHE Consulting published a report on data governance arrangements for real-world evidence (RWE) covering the specifics under which RWE was used in eight different countries: Australia, France, Germany,…
The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
12 October 2022
…represent each country’s individual contribution; Line represents each country’s share in percentages; Green bar represents the EU contribution, including Germany, France, and Italy; To avoid double-counting the GDP of Germany,…
Health Care without Frontiers?
1 December 2000
…and utilisation of a much more effective database than currently exists. Nonetheless, three case studies are described in some detail: a study of cross-border flows between France and Italy; an…
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
1 March 2017
…marketing authorisation in the EU. These OMPs are most widely accessible in Germany and France. In the other countries between 30% and 60% of OMPs are reimbursed. In England, less…